{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:14:42Z","timestamp":1778714082220,"version":"3.51.4"},"reference-count":55,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Myelofibrosis (MF) is a complex and clinically heterogeneous myeloproliferative neoplasm, presenting significant challenges for patient care and clinical decision making. Although global guidelines exist for MF management and continue to evolve with the advent of novel therapies, they do not consider regional variations in drug accessibility nor the availability of diagnostic tools and resources. The notable gap in regional guidance for managing patients with MF in the Asia-Pacific (APAC) region has led to regional disparities in patient care practices. To bridge this gap, a steering committee (SC) of 14 expert hematologists from the APAC region collaborated to develop evidence- and consensus-based consensus statements (CSs) for MF management in the APAC region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>On the basis of evidence from a systematic literature review and their own clinical experience, the SC drafted 13 clinical practice recommendations across four consensus themes: (1) defining the thresholds for anemia and when to initiate or modify treatment; (2) defining when to initiate or modify treatment for thrombocytopenia; (3) defining Janus kinase inhibitor failure and what would warrant switching treatment; and (4) defining the most appropriate risk stratification model for MF in the APAC region. The SC and an extended faculty (EF) of 47 hematologists and two patients voted on the CSs in a modified Delphi process using a 9-point scale (1 = strongly disagree, 9 = strongly agree), with consensus achieved when 75% agreed within the range of 7-9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Following amendments to align with EF feedback, consensus was achieved for all 13 CSs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>These CSs offer pragmatic guidance tailored to the MF landscape in the APAC region, which aims to enhance the quality of patient care and outcomes. The CSs in this study are formally endorsed by the Asian Myeloid Working Group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-24-00916","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T19:59:10Z","timestamp":1752782350000},"page":"821-833","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance"],"prefix":"10.1200","volume":"22","author":[{"given":"Keita","family":"Kirito","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Chuo-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-4239","authenticated-orcid":false,"given":"Chul Won","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-083X","authenticated-orcid":false,"given":"Than","family":"Hein","sequence":"additional","affiliation":[{"name":"Department of Haematology, Singapore General Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-4845","authenticated-orcid":false,"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Won","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-6978","authenticated-orcid":false,"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4836-4929","authenticated-orcid":false,"given":"Garret M.K.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa G.M.","family":"Ooi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponlapat","family":"Rojnuckarin","sequence":"additional","affiliation":[{"name":"King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-7922","authenticated-orcid":false,"given":"Lee-Yung","family":"Shih","sequence":"additional","affiliation":[{"name":"Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4356-6146","authenticated-orcid":false,"given":"Winnie Z.Y.","family":"Teo","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore"},{"name":"Fast and Chronic Program, Alexandra Hospital, Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4893","authenticated-orcid":false,"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017423"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7968"},{"key":"e_1_3_8_4_2","first-page":"456","article-title":"JAK inhibitors in the treatment of myelofibrosis","volume":"20","author":"Levavi H","year":"2022","unstructured":"Levavi H, Hoffman R, Marcellino BK: JAK inhibitors in the treatment of myelofibrosis. Clin Adv Hematol Oncol 20:456-467, 2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_8_5_2","unstructured":"JAKAFI\u00ae (ruxolitinib) tablets for oral use. US Prescribing Information Incyte Corporation 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202192s028lbl.pdf"},{"key":"e_1_3_8_6_2","unstructured":"JAKAVI\u00ae (ruxolitinib). Summary of product characteristics Novartis Europharm Limited 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jakavi"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_8_9_2","unstructured":"INREBIC\u00ae (fedratinib) capsules for oral use. US Prescribing Information Bristol-Myers Squibb 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212327s007lbl.pdf"},{"key":"e_1_3_8_10_2","unstructured":"INREBIC\u00ae (fedratinib). Summary of product characteristics Bristol Myers Squibb 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inrebic"},{"key":"e_1_3_8_11_2","unstructured":"VONJO\u00ae (pacritinib) capsules for oral use. US Prescribing Information Swedish Orphan Biovitrum AB(publ) (Sobi) 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208712s003lbl.pdf"},{"key":"e_1_3_8_12_2","unstructured":"OJJAARA\u00ae (momelotinib) tablets for oral use. US Prescribing Information GlaxoSmithKline 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/216873s002lbl.pdf"},{"key":"e_1_3_8_13_2","unstructured":"OMJJARA\u00ae (momelotinib). Summary of product characteristics GlaxoSmithKline 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/omjjara"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.01.006"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1944096"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_8_25_2","unstructured":"GSK\u2019s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis. GSK 2024. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01261-x"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.015"},{"key":"e_1_3_8_28_2","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for myeloproliferative neoplasms V.1.2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000732"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003314"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000963"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204602"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.10.016"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1046866"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.004"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.01.016"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13570"},{"key":"e_1_3_8_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000424"},{"key":"e_1_3_8_40_2","first-page":"383","article-title":"Spleen volume assessment in Ph-negative chronic myeloproliferative neoplasms: A real-life study comparing ultrasonography vs. magnetic resonance imaging scans","volume":"104","author":"Pugliese N","year":"2025","unstructured":"Pugliese N, Cavaliere C, Basso L, et al: Spleen volume assessment in Ph-negative chronic myeloproliferative neoplasms: A real-life study comparing ultrasonography vs. magnetic resonance imaging scans. Ann Hematol 104:383-388, 2025","journal-title":"Ann Hematol"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00878-8"},{"key":"e_1_3_8_42_2","first-page":"2901","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann N","year":"2023","unstructured":"Gagelmann N, Badbaran A, Salit RB, et al: Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood 141:2901-2911, 2023","journal-title":"Blood"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006889"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000818"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0107-z"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867"},{"key":"e_1_3_8_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-890889"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.169"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633404"},{"key":"e_1_3_8_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"key":"e_1_3_8_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35489"},{"key":"e_1_3_8_55_2","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for hematopoietic cell transplantation (HCT) V.2.2025. https:\/\/www.nccn.org"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022345"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-24-00916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:05:35Z","timestamp":1778713535000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-24-00916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1200\/OP-24-00916"],"URL":"https:\/\/doi.org\/10.1200\/op-24-00916","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2024-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}